ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

CMV Risk Status Remains a Relevant Risk Factor for Long-Term Outcomes

G. Karadkhele, W. Zhang, C. P. Larsen

Emory University, Atlanta, GA

Meeting: 2019 American Transplant Congress

Abstract number: 10

Keywords: Cytomeglovirus, Kidney transplantation, Risk factors, Survival

Session Information

Date: Sunday, June 2, 2019

Session Name: Concurrent Session: Kidney Complications: Late Graft Failure I

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:30pm-3:42pm

Location: Veterans Auditorium

Related Abstracts
  • CMV-Specific CD154+T-Cells and CMV Disease Status After Liver Or Intestine Transplantation (LTx, ITx)
  • Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients

*Purpose: Intensification of immunosuppression using T cell depleting induction has reduced rates of acute cellular rejection after kidney transplantation. Belatacept, a first in class T cell costimulation blocker avoids CNI nephrotoxicity, inhibits donor specific antibody formation and improves survival after kidney transplant. While offering advantages in controlling alloimmunity these approaches perturb protective immunity. Despite the use of antiviral agents CMV remains a source of morbidity. We sought to understand the impact of cmv risk status on survival outcomes using current immunosuppressive regimens.

*Methods: To determine impact of cmv risk status on kidney transplant survival outcomes (death, death censored graft loss or a composite of the two) in the US we analyzed primary kidney transplants performed between 2006-2017 using data from SRTR and our local program data. Descriptive statistics, Kaplan-Meier (KM) and Cox model analyses were performed with R (survival and survminer).

*Results: The SRTR cohort consisted of 99,312 recipients of deceased (dd) and 52,643 living donor (ld) kidneys. Distribution by CMV risk status was low 17%, moderate 65% and high 18%. Our local cohort contained 2124 dd and 762 ld recipients with similar CMV risk. KM analysis (Fig 1 and 2) showed a significant difference by CMV risk status for each data set (p< 0.01). In SRTR data CMV high risk was status was a significant predictor of each of the survival outcomes in Cox proportional hazard and adjusted survival while including donor type, race, induction type and recipient age in the model (HR 1.19, p < 0.007). Donor type, race but not induction were also significant in the model. In our local data CMV high risk was also an independent predictor of survival (HR 2.07, p 0.024) as was donor type, but not race or use of belatacept vs. tacrolimus.

*Conclusions: CMV high risk status remains an important predictor of morbidity and mortality in the current era irrespective of induction or primary maintenance therapy. Further study of the duration, magnitude, and recurrence of viremia by induction and maintenance should be undertaken. Directing organs from CMV negative deceased and or living donors to CMV negative recipients could improve survival. Studies to model to impact on survival, cost and waiting time should be considered.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Karadkhele G, Zhang W, Larsen CP. CMV Risk Status Remains a Relevant Risk Factor for Long-Term Outcomes [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/cmv-risk-status-remains-a-relevant-risk-factor-for-long-term-outcomes/. Accessed March 2, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Enhanced Recovery after Surgery Protocols in Kidney Transplantation: Time to Change Practice?
  • Efficacy of Filgrastim in Solid Organ Transplant Recipients
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • #16789 (not found)
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.